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Purpose: The prescribing of oral chemotherapy agents has introduced the new challenge of 
ensuring patients’ adherence to therapy. Aspects of a close patient–doctor relationship are 
reported to be correlated with adherence to oral anticancer drugs, but data on capecitabine 
are scarce.
Patients and methods: Sixty-four outpatients with a diagnosis of cancer and prescribed 
capecitabine were recruited from a German Comprehensive Cancer Center. We used the 
Patient–Doctor Relationship Questionnaire (PDRQ-9), the Medical Adherence Rating Scale 
(MARS), the Beliefs about Medicines Questionnaire (BMQ), and the Satisfaction with Informa-
tion about Medicines Scale (SIMS) to assess patients’ perceptions and behavior. Medical data 
were extracted from the charts.
Results: Non-adherence was reported by 20% of the 64 participants. The perceived quality 
of the patient–doctor relationship was high in general, but it did not emerge as a predictor of 
adherence in our survey (odds ratio [OR]=0.915, P=0.162, 95% CI=0.808–1.036). However, 
beliefs about medicine (OR=1.268, P,0.002; 95% CI=1.090–1.475) as well as satisfaction 
with information about medicine (OR=1.252, P,0.040, 95% CI=1.010–1.551) were predic-
tors of adherence and the quality of the patient–doctor relationship was correlated with both 
variables (r=0.373, P=0.002 for SIMS sum score; r=0.263, P=0.036 for BMQ necessity/concern 
difference). Overall, adherence to capecitabine was high with a conviction that the therapy is 
necessary. However, concerns were expressed regarding the long-term effect of capecitabine 
use. Patients have unmet information needs regarding interactions of capecitabine with other 
medicines and the impairment of their intimate life.
Conclusions: In order to ensure adherence to capecitabine, our results seem to encourage 
the default use of modern and perhaps more impersonal means of information brokerage 
(eg, email, internet). However, the contents of some of patients’ informational needs as well as 
the associations of patients’ beliefs and satisfaction about the information received suggest a 
benefit from a trustful patient–doctor relationship.
Keywords: oral anticancer drugs, capecitabine, adherence, patient–doctor relationship, beliefs 
in medication, satisfaction with information about medicines
Introduction
With progress in diagnostics and therapy, cancer is becoming more and more a chronic 
disease. In the case of most numerous cancer entities (ie, colon or breast cancer), and 
especially if the tumor has spread out to surrounding tissue or to lymph nodes, patients 
will usually receive chemotherapy protocols, some of them based on 5-fluorouracil 
(5-FU).1 Such protocols are regarded as crucial for the treatment of patients in the 
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upcoming years.2–4 5-FU, which is usually administered 
intravenously, typically causes various side effects common 
in drugs directed nonspecifically at fast growing cells.5 The 
prodrug capecitabine, that converts to 5-FU within tumors, 
allowed to reduce the spectrum and magnitude of side effects. 
Its oral administration has also shown efficacy and safety 
comparable to intravenous fluorouracil, and was preferred 
by patients.1,6,7 Even though there are apparent benefits to 
oral drug administration, health care professionals are fac-
ing new challenges. Dose is controlled when intravenously 
administered by a member of the health care staff. With oral 
therapy self-managed by patients, however, the dosage is 
not externally controlled. There is little research on adher-
ence to capecitabine, and adherence rates ranging between 
60% and 90% have been demonstrated.8–19 Even less is 
known about the risk of over-adherence in patients receiving 
capecitabine.20–22 Although the numbers generally appear to 
be satisfying, even a small variation of adherence may result 
in adverse clinical consequences.14,20–23
If patients do not take the prescribed medication as 
intended by the prescribing person, this can happen due to 
lack of ability or willingness, and may often be a mixture of 
intentional and unintentional aspects.24
Indicators of a close patient–doctor relationship (ie, to 
involve patients in the process of decision making, to treat 
them as equals, and to avoid unresolved issues regarding 
prescriptions) were linked to adherence to medication in 
a large study comprising 45,700 patients from 24 European 
countries.25 Data on oral anticancer drugs are scarce, mostly 
focusing on endocrine therapy after breast cancer, and 
indicating that a good and trustful patient–doctor relation-
ship is connected with a higher disposition to execute doc-
tors’ instructions regarding medication and adherence.26–29 
To our knowledge, only 1 publication with 130 patients 
from Malaysia exists reporting a linear relationship 
between satisfaction with health care and adherence to 
capecitabine.18
Predictors of adherence that have been more frequently 
cited are perceptions of illness and medication. These factors 
are influenced by the information available to patients.30–32 
Research results hint to the fact that many patients have a 
rather negative perspective concerning pharmaceuticals, 
assessing them generally as harmful, permanently weighing 
their convictions regarding the necessity of medication 
(perceived benefits) against their worries about possible 
negative impacts (perceived risks).31,33 Data from oncological 
studies show a connection between cancer patients’ doubts 
concerning the efficacy of the treatment, worries about side 
effects, depressive symptoms, and poorer adherence, for 
example.29,34,35 Patients who have doubts about the necessity 
of their medication may more likely willfully skip or reduce 
doses, or may be more inclined to forget to take their medica-
tion. Likewise, patients who are highly concerned about side 
effects may reduce the dosage on purpose in order to reduce 
the suspected risk.31
Regarding capecitabine, 2 studies focused on patients’ 
medication-related convictions and their satisfaction with 
the information obtained, and did not find a significant con-
nection with adherence.14,23 The authors claimed that the 
high adherence rate in both samples could have influenced 
the results.14,23
However, Bhattacharya et al found that patients’ satisfac-
tion with the information they had received on capecitabine 
correlated negatively with high concerns regarding the 
medication.23
To our knowledge, data on the association between the 
patient–doctor relationship and beliefs about capecitabine as 
well as satisfaction with information on this specific drug are 
lacking. Only Grassi et al reported a link between percep-
tions of a supportive role of the doctor and beliefs about the 
necessity of an antitumor therapy.36 Regarding the relevance 
of capecitabine, more insight into factors influencing adher-
ence is needed. Therefore, this study examined associations 
between patients’ perceptions of their relationship with 
doctors and adherence. Furthermore, associations between 
those perceptions and beliefs about their cancer treatment as 
well as satisfaction with the information about their medicine 
were examined.
We hypothesized that poorer patient–doctor relationship 
would be related to negative beliefs about cancer medica-
tion, lower satisfaction with information about medication, 
and lower adherence rates. Exploring those associations 
and identifying possible opportunities for improvement can 
help health care professionals to enhance services related 
to prescribing medicines such as capecitabine in order to 
ameliorate adherence.
Subjects and methods
Participants
The study design was a cross-sectional single center study. 
We recruited cancer patients undergoing chemotherapy 
with capecitabine at outpatient clinics, day hospitals and 
doctors’ offices of the Comprehensive Cancer Center of the 
University of Wuerzburg, Germany. These units started to 
cooperate just recently and our commitment was to moni-
tor adherence from the outset. Participants were recruited 
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from September 1, 2015 to March 1, 2017. They were able 
to participate in this trial after providing written informed 
consent. The study procedure was previously approved by 
the Medical Faculty’s Ethics Committee of Wuerzburg 
University, Germany, in accordance with the Declaration 
of Helsinki.
Measures
1. The Patient–Doctor Relationship Questionnaire 9
(PDRQ-9) consists of 9 items, and is aimed at captur-
ing patients’ perception of the relationship with their
physician.37,38 Central items are inquiring whether patients
are experiencing a trustworthy, communicative relation-
ship with an effective and helpful health professional.37,38
The response format is a 5-point scale ranging from
1 (not at all) to 5 (totally). The higher the scores, the
higher the patient’s satisfaction with the patient–doctor
relationship.37
2. The Medication Adherence Report Scale (MARS) is a
5-item self-report instrument focusing on non-adherent
behavior (like “I forgot to take them” or “I alter the
dose”).39 The possible answers range from 1 (always) to
5 (never) on a 5-point Likert scale (overall range from 5
to 25). Lower scores are interpreted as indicators of lower
levels of adherent behavior.39 In our context, patients
scoring less than 25 were considered as non-adherent.
3. The Satisfaction with Information about Medicines
Scale (SIMS) is a questionnaire aiming at evaluating the
extent to which patients feel satisfied with the informa-
tion they have received about prescribed drugs.32 Each
of its 17 items refers to a particular aspect of medicine
use. Participants can assess the amount of information
they have received according to the following response
categories: “too much”, “about right”, “too little”, “none
received”, “none needed”. There are 3 levels of response
analysis: a detailed medicine information profile, result-
ing from examining the ratings for each individual item
in order to identify individual kinds of information that
patients feel they are missing; a total satisfaction rating,
resulting from summing up the scores for each item;
and two subscale scores, identifying patients’ satisfac-
tion with information about the action and usage of
medication (items 1–9), and the potential problems of
medication (items 10–17). Ratings with “about right” or
“none needed,” indicating the patient’s satisfaction with a
particular aspect of medication information, are assigned
a score of 1. Ratings of “too much,” “too little,” or “none
received,” indicating the patient’s dissatisfaction with the
information provided, are scored 0. A range from 0 to 17 
is covered, with high scores standing for a high degree 
of overall satisfaction with the amount of information 
received on the medication. 
4. The Beliefs about Medicines Questionnaire (BMQ)
includes 2 scales of 5 items each assessing patients’
beliefs about the necessity of the prescribed medica-
tion in order to control their disease and their concerns
about possible negative consequences of taking it.31 The
response format to indicate the degree of agreement with
each statement is a 5-point Likert scale, ranging from 1
(strongly disagree) to 5 (strongly agree). Individual item
scores within both scales are summed up. Thus, total
scores for the Necessity and Concerns Scales range from
5 to 25. Higher scores indicate stronger beliefs; scores
above 12.5 indicate strong belief.31 A necessity–concerns
differential is calculated as the difference between the
necessity and the concerns scales, with a possible range
of -20 to +20. This differential can be thought of as the
cost–benefit analysis for each patient, for whom costs
(concerns) are weighed against their perceived benefits
(necessity beliefs).31
5. Clinical and sociodemographic variables were extracted
from the charts. Patients were invited to score their per-
ceived burden of common side effects on a visual analog
scale with a range from 0 (not at all) to 100 (maximum).
statistical analyses
The data were mainly at ordinal or categorical level or did 
not follow a normal distribution. Hence, non-parametric 
testing was employed. SPSS version 24 was used for data 
analysis. Medians and interquartile range (IQR, 25%- and 
75%-quantiles) within the participant population were calcu-
lated using appropriate descriptive statistics. For categorical 
parameters, absolute and relative frequencies were reported. 
The comparison of 2 interval data sets was carried out 
using Spearman’s rank correlation coefficient, and Mann–
Whitney’s U-analysis for dichotomized data.
Multivariate logistic regression models were used to 
identify the independent factors associated with adherence 
to capecitabine, with adjustments for age, gender and time 
since diagnosis.40,41 Variables with a P-value of 0.25 or less 
in the bivariate analyses were integrated in a multivariate 
logistic regression model employing the backward variable 
selection method. Odds ratios and 95% confidence intervals 
(95% CI) were computed for each variable in the final model, 
P,0.05 (2-sided) was regarded as statistically significant in 
all statistical tests.
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Results
sociodemographics and clinical data
Sixty-four patients completely filled in their questionnaires. 
Females accounted for 17 participants (27%) of the sample, 
and the mean (SD) age was 66 (±12.1) years (Table 1). 
Capecitabine was part of a combination therapy for 22 (34%) 
participants, while 25 (39%) had a palliative rather than an 
active treatment regime. Fifty-four (84%) participants were 
diagnosed with colorectal cancer. Other diagnoses were 
stomach cancer (n=6; 9%), breast cancer (n=2; 3%), pancre-
atic cancer (n=1; 2%) and an epithelial tumor of unknown 
origin (n=1; 2%). Table 1 also presents relevant clinical data 
for the sample population. Participants were mostly in their 
second year from cancer diagnosis and in their first year of 
capecitabine treatment. The most troubling side effect was 
hand-foot syndrome (median=35, IQR 1.25–80), followed 
by fatigue (median=30, IQR 15–60). Figure 1 presents the 
extent to which participants declared to feel troubled by the 
side effects most frequently reported.
satisfaction with patient–doctor 
relationship
Median of the mean score on the PDRQ-9 was 4.61 (IQR 
4–5), indicating a high satisfaction of patients with their 
relationships with their doctors. Most of the patients were 
convinced that their physician was dedicated to helping them 
(67%); they perceived that their physician was easily acces-
sible (63%) and that communication was straightforward 
(63%, Table S1, Figure S1).
Adherence
Thirteen participants reported non-adherence, and 2 of them 
reported multiple methods of deviation. Forgetting to take a 
dose was the method of deviation reported most frequently, 
and the extent to which this occurred was mainly described 
as “rarely” by participants (Table S2). Participants reporting 
non-adherent behavior and those reporting no deviation 
did not differ significantly in demographic or clinical 
characteristics.
Patient beliefs about medication
The sample’s positive median (IQR) BMQ differential 
score was 4.00 (0.26–8.75). This can be interpreted as 
participants’ beliefs in necessity on average outweighing 
concerns about capecitabine treatment. Fifty-nine (92%) 
patients scored .12.5 on the BMQ-N subscale, which indi-
cates their strong beliefs in the necessity of capecitabine 
treatment. Forty-three (67%) participants scored .12.5 on 
the BMQ-C subscale, indicating strong concerns regarding 
capecitabine treatment. The necessity–concerns differential 
yielded negative results for 13 participants, indicating that 
concerns regarding oral anticancer therapy outweighed 
necessity beliefs. The strongest necessity beliefs were for 
“My health in the future will depend on this medicine”, 
for “My health, at present, depends on this medicine” and 
“Without this medicine I would be very ill”. The strongest 
Table 1 sociodemographic and medical characteristics of out-
patients receiving capecitabine (n=64)
Time n %
64 100
Age, mean
(sD; range)
66 years
(12; 28–89)
gender
Female
Male
17
47
27
73
Family status
Married
not married
46
18
72
28
education
secondary school
higher education
41
23
64
36
Tumor entity
colorectal cancer
stomach cancer
Breast cancer
Pancreatic cancer
cancer of unknown origin
54
6
2
1
1
84
9
3
2
2
Tumor depth
T1
T2
T3
T4
TX
4
14
26
18
2
6
22
41
28
3
lymph nodes
n neg
n pos
24
40
38
63
Metastasis
M neg
M pos
46
18
72
28
regimen
Adjuvant
Palliative
39
25
61
39
capecitabine
Monotherapy
combined therapy
42
22
66
34
Time since tumor diagnosis, mean
(sD; range)
19 months
(34; 1–185)
Time since cap treatment, mean
(sD; range)
7 months
(9; 1–50)
Abbreviations: n neg, no regional lymph node metastases; T1, tumor invades 
submucosa; n pos, metastasis to regional lymph nodes; T2, tumor invades 
muscularis propria; T3, tumor invades through the muscularis propria into the 
pericolorectal tissues; M neg, no distant metastasis; M pos, metastasis to distant 
organs; T4, tumor penetrates visceral peritoneum or invades to other organs or 
structures; TX, primary tumor cannot be assessed; cap, capecitabine.
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concerns referred to long term effects of capecitabine intake 
(Figures S2 and S3).
satisfaction with information about 
medicines
Figure 2 demonstrates the distribution of responses of the 
SIMS. Eleven participants reported complete satisfaction 
with the information provided about capecitabine therapy. 
Missing information or dissatisfaction with the information 
provided was mostly reported for the questions of whether 
the medication will affect one’s sex life and whether 
capecitabine interferes with other drugs. The median of the 
subscale on patients’ satisfaction with information about 
the action and usage of medication was 6.7 (IQR 6–9). The 
median of the subscale on potential problems of medication 
was 5 (IQR 4–7).
Potential predictors of outcome 
measures
Sociodemographic variables, clinical variables including 
side effects and adherence did not correlate significantly 
(Tables 2 and 3). The P-value in the bivariate analyses of 
         
)HYHURULQIHFWLRQ
9RPLWLQJ
1DXVHD
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±
Figure 1 Perceived burden of side effects on a visual analog scale (VAs, 0–100).
Figure 2 Participant satisfaction with information received (satisfaction with information about Medicines scale, n=64).
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PDRQ-9 sum score and adherence was 0.23. Furthermore, 
there were no significant correlations between the PDRQ-9 
single item score and adherence.
Significant small to moderate positive correlations could 
be found between the PDRQ-9 sum score and the SIMS sum 
score (Spearman’s r=0.373, P=0.002), the SIMS subscale 
on action and usage of medication (Spearman’s r=0.268, 
P=0.032), and the SIMS subscale on potential problems of 
medication (Spearman’s r=0.408, P=0.001), respectively. 
These results illustrate that patients who were more satisfied 
with the patient–doctor relationship were generally more 
satisfied with the information received about their medicine. 
Those patients also reported greater satisfaction with the 
received information about action, usage and potential prob-
lems of their medication.
Furthermore, a small positive correlation between the 
PDRQ-9 and the BMQ necessity–concerns differential 
(Spearman’s r=0.263, P=0.036) was detected, suggesting 
that those patients outweigh necessities against concerns and 
fears regarding their therapy.
Two logistic regression models were investigated, both 
with adherence as dependent variable. In the first model, 
the sum scores of BMQ, SIMS and PDRQ-9 were used as 
predictors. In the second model, the predictors were the sub-
scores of BMQ and of SIMS. There were no confounding 
factors adjusted for as we found no significant correlations 
between sociodemographic and medical variables with adher-
ence in our sample. The requirements of logistic regression 
(no multicollinearity, no outliers, log linearity) were checked 
with appropriate methods and were met in both models.
Nagelkerke’s R2 for the logistic regression model 
including sum scores of BMQ, SIMS and PDRQ-9 was 
0.291, and for the model including subscores of BMQ 
and SIMS was 0.309, respectively. The BMQ sum score 
Table 2 correlations between adherence and sociodemographic and medical variables (n=64) using Mann–Whitney U-test 
Variable Median IQR Mean 
rank
Sum of 
ranks
U Z P-value
Age
Adherent
non-adherent
69 years
65 years
57–76
54–73
33.71
28.88
1,618.00
462.00
326.000 0.900 0.368
Tumor depth (T1–T4)
Adherent
non-adherent
3
3
2–4
2–4
33.35
33.94
1,601.00
479.00
343.000 -0.670 0.503
Time since tumor diagnosis
Adherent
non-adherent
7 m
9 m
4–16
3–13
32.43
32.72
1,556.50
523.50
380.500 -0.054 0.957
Time since cap treatment
Adherent
non-adherent
3 months
4 months
2–8
2–7
32.76
31.72
1,572.50
507.50
371.500 -0.195 0.845
hFs
Adherent
non-adherent
37.5
27.5
2.5–80.0
1.3–63.8
33.42
29.76
1,604.00
476.00
340.000 -0.689 0.491
Fatigue
Adherent
non-adherent
37.5
22.5
20–67.5
0–50
34.61
26.16
1,661.50
418.50
282.500 -1.581 0.114
Diarrhea
Adherent
non-adherent
7
5
0–28.8
0–50
31.93
34.22
1,598.50
547.50
356.500 -0.446 0.656
Mucositis
Adherent
non-adherent
5
2.5
0–20
0–40
32.25
32.25
1,548.00
532.00
372.000 -0.197 0.844
nausea
Adherent
non-adherent
5
2.5
0–30
0–15
33.30
30.09
1,598.50
481.50
345.500 -0.632 0.528
Vomiting
Adherent
non-adherent
0
0
0–5
0–5
31.88
32.34
1,498.50
517.50
370.500 -0.109 0.913
Fever
Adherent
non-adherent
0
0
0–0
0–0
32.67
32.00
1,568.00
512.00
376.500 -0.577 0.564
Abbreviations: cap, capecitabine; iQr, interquartile range; U, Mann–Whitney U-test; Z, Kolmogorov–smirnov Z; hFs, hand-foot syndrome.
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(OR=1.268, P=0.002, 95% CI=1.090–1.475), the SIMS 
sum score (OR=1.252, P=0.040; 95% CI=1.010–1.551) 
and the BMQ concern subscore (OR=1.374, P=0.003, 
95% CI=1.112–1.699) were detected as significant positive 
predictors of adherence. The effect of the PDRQ-9 sum 
score (OR=0.915, P=0.162; 95% CI=0.808–1.036) as well 
as of the BMQ-necessity subscale (OR=1.139, P=0.120, 
95% CI=0.967–1.343) or the SIMS subscales (action and 
usage OR=1.179, P=0.426, 95% CI=0.768–1.770; potential 
problems OR=1.352, P=0.097, 95% CI=0.947–1.930) on 
adherence were not significant (Tables 4 and 5).
Discussion
We initiated a survey on the associations between the patient–
doctor relationship and beliefs or satisfaction with informa-
tion about capecitabine in a sample of outpatients treated with 
oral capecitabine in the clinical setting of a German Compre-
hensive Cancer Center. The patient-reported adherence rate 
to capecitabine of 80% in our study is in line with previous 
research results based on different types of monitoring.8–19 The 
non-adherence reported was primarily “forgetting,” a reason 
for deviation which is thought of as more socially acceptable 
by patients than intentional behaviors (ie, missing or altering 
a dose).23,42–45 Almost three-quarters of the participants were 
men (n=47, 73%), and about one third suffered from meta-
static illness. The primary tumor sites were mainly colorectal 
(84%), gastric (9%), and breast cancer (3%). Sixty-four 
percent of patients received capecitabine as a monotherapy. 
The mean time since tumor diagnosis and start of capecitabine 
therapy was 19 and 7 months, respectively. Hand-foot syn-
drome followed by fatigue was reported by most participants 
to be troubling, which is in line with other studies.23
We found no correlations between sociodemographic or 
clinical characteristics, perceived intensity of side effects and 
adherence, which is counterintuitive at first sight but in line 
with other studies reporting mixed results.8,10,12,13,19,46,47
Table 3 correlations between adherence and sociodemographic 
and medical variables (n=64) using Fishers exact test
Variable n OR 95% CI P-value
Gender 1.000
Male
Adherent 
non-adherent
35
12
1.029 0.739–1.433
Female
Adherent 
non-adherent
13
4
0.923 0.351–2.429
Family status 0.756
Married
Adherent 
non-adherent
35
11
0.943 0.650–1.369
not married
Adherent 
non-adherent
13
5
1.154 0.487–2.733
Lymph nodes 0.866
Positive
Adherent
non-adherent
25
10
0.980 0.710–1.560
negative
Adherent
non-adherent
23
6
1.300 0.367–2.489
Metastasis 0.756
Positive
Adherent
non-adherent
5
13
1.154 0.487–2.733
negative
Adherent
non-adherent
35
11
0.943 0.650–1.369
Regimen 0.561
Adjuvant
Adherent
non-adherent
28
11
1.179 0.784–1.772
Palliative
Adherent
non-adherent
20
5
0.750 0.337–1.669
Capecitabine 1.000
Monotherapy
Adherent
non-adherent
31
11
1.065 0.720–1.574
combination therapy
Adherent
non-adherent
17
5
0.882 0.388–2.006
Table 4 logistic regression model on adherence with sum scores 
as predictors. nagelkerke’s R2 .291
B SE P-value OR 95% CI
Adherence
Predictor variables
BMQ sum score 0.237 0.077 0.002 1.268 1.090–1.475
siMs sum score 0.224 0.110 0.040 1.252 1.010–1.551
PDrQ sum score -0.089 0.064 0.162 0.915 0.808–1.036
constant -5.810 3.138 0.064 0.003
Abbreviations: B, intercept; se, standard error; BMQ, Beliefs about Medicines 
Questionnaire; siMs, satisfaction with information about Medicines scale; PDrQ, 
Patient–Doctor relationship Questionnaire.
Table 5 logistic regression model on adherence with subscores 
as predictors. nagelkerke’s R2 .309
B SE P-value OR 95% CI
Adherence
Predictor variables
BMQ subscore necessity 0.130 0.084 0.120 1.139 0.967–1.343
BMQ subscore concerns 0.318 0.108 0.003 1.374 1.112–1.699
siMs subscore 0.165 0.207 0.426 1.179 0.768–1.770
Action and usage
siMs subscore 0.301 0.182 0.097 1.352 0.947–1.930
Potential problems
constant -8.428 3.239 0.009 0.000
Abbreviations: B, intercept; se, standard error; BMQ, Beliefs about Medicines 
Questionnaire; siMs, satisfaction with information about Medicines scale.
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Results of the PDRQ-9 show a high level of patients’ 
satisfaction with the relationship with their doctors (M=4.43, 
SD=0.63). The levels of satisfaction regarding the total score 
as well as single items are in fact higher than in a represen-
tative German survey focusing on the relationship with the 
family physician.48
Contrary to our assumption, neither the patients’ evalu-
ation of the patient–doctor relationship in general nor single 
aspects of this relationship were predictors of adherence to 
oral capecitabine therapy. Our results seem to contradict 
those of Zahrina et al, where satisfaction with care was 
associated with adherence.18 In our study, we focused pri-
marily on the patient–doctor relationship, whereas Zahrina 
et al examined satisfaction with appointments and pharmacy 
services as well.18
Our data represent the association between the perceived 
interactions with doctors and satisfaction with information 
about capecitabine. At the same time, fewer patients in our 
study (17%) were totally satisfied with the information 
received than in previous reports (60%).23 The participants 
expressed their request for (more) information on how 
capecitabine may affect their sex life. Further studies may 
help to ascertain the importance of the topic to this popula-
tion. However, we believe that health care professionals may 
increase levels of satisfaction by referring empathically to 
this topic and providing information. Although connections 
between the use of capecitabine, alcohol intake and hand-
foot syndrome have been reported, many patients did not 
know whether alcohol consumption was allowed during 
therapy.49 The lack of satisfaction with information regarding 
drug interactions was also of concern in a sample where the 
majority used additional medication.49
We found associations between patients’ perceptions 
of their interactions with their doctors and beliefs about 
anticancer treatment, a result also described by Grassi 
et al.36 In line with their results we show that patients 
perceiving their doctors as supportive and empathic were 
more likely to believe that their therapy was necessary and 
were less likely to be concerned about it. These data con-
firm and expand the literature on cancer patients’ beliefs 
about medication by highlighting the possible role of the 
patient–doctor relationship.36 Regarding the BMQ question-
naire, our patients valued the beliefs about necessities of 
medication over the concerns about medication (4.77); the 
difference is notably smaller than in previous studies (7.8).23 
Although patients reported concerns about capecitabine 
therapy, these were outweighed by the conviction that it is 
necessary. Regarding other chronic conditions, it is known 
that perceived necessity can be considerably lower and our 
results may reflect patients’ notions of cancer as an especially 
threatening condition.31,50
In contrast to studies with similar adherence rates, 
we found that satisfaction with information as well as 
beliefs about capecitabine were predictive of adherence 
(CI=1.2–1.3).14,23 We did not examine mediator effects of 
the PDRQ-9 in this context.
Scores of the SIMS and the BMQ were correlated in 
the sense that patients who were more satisfied with the 
information they had received were more convinced that 
medication with capecitabine was necessary. Satisfaction 
with information about capecitabine, however, was nega-
tively related to concerned beliefs about the drug, as has 
been described before.23 This named relationship is likely 
to be mutually reinforcing. Patients who are unhappy 
with the information provided are likely to be more con-
cerned about their therapy. At the same time, those more 
concerned about drug intake are likely to wish for more 
information.23
Our study has several limitations. The sample size is 
small and has been drawn from a single Comprehensive 
Cancer Center (CCC). The single units of the CCC started 
only recently and we conducted this initial survey for about 
18 months. Due to organizational reasons, we could not 
obtain data on the majority of breast cancer patients and were 
not able to obtain data on dropouts. Larger sample sizes and 
preferentially multicenter studies are necessary to produce 
more generalizable results. For example, we cannot explain 
why concerns about medication also predicted adherence. 
It would be of great interest to us whether these data will be 
replicated in larger surveys.
We believe that a good patient–doctor relationship may 
act indirectly on adherence via beliefs and satisfaction with 
information about capecitabine. From a mathematical point 
of view though, we refrained from calculating moderator 
effects due to the small sample size. Furthermore, the number 
of variables and interrelationships in our study may lead to 
errors by multiple testing. The significant P-value was not 
adjusted as we intended to broadly explore patients’ experi-
ences in daily practice. Regarding the screening instruments, 
patients’ perceptions were surveyed with questionnaires, 
while clinical interviews could have provided more specific 
information. Also, due to a self-presentation bias possibly 
resulting in overestimation, self-reported adherence ratings 
should be treated cautiously.51 Ultimately, all existing 
measures of adherence have their shortcomings, as they are 
neither objective nor very suitable for daily practice.52,53 Up 
till today, a well-validated scale designed particularly for 
oral anticancer drugs adherence has not yet been developed.54 
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Most adherence scales used contain items focusing on 
measuring patients’ behavior related to taking their medica-
tion rather than their perceptions and beliefs. Another major 
limitation of our approach is the fact that we did not screen 
for over-adherence, a phenomenon which may lead to adverse 
reactions and may result from misunderstandings or flawed 
communication.20 We are therefore not able to expand the 
literature on this issue of increasing relevance.20–22 Finally, 
future studies may also benefit from measuring changes of 
patients’ perceptions and adherence over time, as we only 
adopted a cross-sectional design. Longitudinal studies may 
reveal significant associations at certain timepoints, ie, at the 
beginning of treatment.
On the other hand, our study provides valuable informa-
tion and constructive suggestions for future research. It is 
well established that adherence should be monitored not only 
in clinical trials but also in daily routine, since the rates of 
adherence with oral medication in the structured environment 
of clinical trials are commonly greater.43,55,56
We decided to use mainly patient-reported outcome 
(PRO) measures, as perceptions that doctors may sometimes 
not be aware of are often the ones that really motivate the 
patient to follow a given treatment.57
In contrast to other reports, information about capecit-
abine as well as beliefs about the drug were examined in a 
narrow sense, ie, restricted to 1 specific pharmaceutical. More 
research on distinct types of cancer medication may provide 
further information.
Summing up, the perceived quality of the patient–doctor 
relationship did not predict adherence to capecitabine in our 
sample. Nevertheless, our findings highlight the importance 
for oncologists to consider patients’ satisfaction within the 
patient–doctor interaction as variables influencing patients’ 
satisfaction with information, as well as variables influencing 
their beliefs and representations of capecitabine. There were 
no distinct results as to whether the quality of the patient–
doctor relationship moderated the effects of information and 
beliefs regarding capecitabine on adherence. We believe that 
this question is worth more specific exploration in larger 
studies. Another implication leads to reports describing 
that the introduction of modern means of communication 
such as text messaging and mobile telephone reminders 
has improved adherence to therapy.58,59 It may well be that 
the direct patient–doctor relationship is less important than 
beliefs and information, which could also be addressed by 
medical professionals other than oncologists. Large studies 
with intensive pharmaceutical interventions are underway 
in order to optimize adherence management.60,61 First 
results on capecitabine are promising.62 Approaches using 
modern means of communication to ameliorate adherence 
to oral anticancer drugs have been proven feasible and well 
accepted, and their results are awaited eagerly.63,64
Publication rights of the german version 
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Table S1 single items of the Patient–Doctor relationship Questionnaire (PDrQ-9, n=64)
Totally 
appropriate
Mostly 
appropriate
Appropriate Somewhat 
appropriate
Not at all 
appropriate*
Item score
N % N % N % N % N % M SD
My physician is dedicated to help me 43 67.2 16 25 5 7.8 4.59 0.64
i can talk to my physician 40 62.5 18 28.1 5 7.8 1 1.6 4.52 0.71
I find my physician easily accessible 40 62.5 18 28.1 5 7.8 1 1.6 4.50 0.78
i feel content with my physician’s treatment 37 57.8 22 34.4 4 6.3 1 1.6 4.48 0.69
My physician helps me 38 59.4 20 31.3 5 7.8 1 1.6 4.48 0.71
i trust my physician 37 57.8 19 29.7 8 12.5 4.45 0.71
My physician understands me 33 51.6 21 32.8 9 14.1 1 1.6 4.34 0.78
My physician and i agree on the nature of 
my medical symptoms
28 43.8 28 43.8 7 10.9 1 1.6 4.30 0.73
My physician has enough time for me 28 43.8 24 37.5 8 12.5 4 6.3 4.19 0.89
Total mean 4.43 0.64
Note: *no patients ticked this column.
3HUFHQWDJHRISDUWLFLSDQWVVDWLVILHGZLWKSDWLHQW±GRFWRUUHODWLRQVKLS
       
0\SK\VLFLDQKDVHQRXJKWLPHIRUPH
0\SK\VLFLDQDQG,DJUHHRQWKHQDWXUHRIP\PHGLFDOV\PSWRPV
0\SK\VLFLDQXQGHUVWDQGVPH
,WUXVWP\SK\VLFLDQ
,IHHOFRQWHQWZLWKP\SK\VLFLDQ¶VWUHDWPHQW
0\SK\VLFLDQKHOSVPH
,ILQGP\SK\VLFLDQHDVLO\DFFHVVLEOH
,FDQWDONWRP\SK\VLFLDQ
0\SK\VLFLDQLVGHGLFDWHGWRKHOSPH
7RWDOO\DSSURSULDWH 0RVWO\DSSURSULDWH $SSURSULDWH 6RPHZKDWDSSURSULDWH 1RWDWDOODSSURSULDWH
Figure S1 Participant satisfaction with Patient–Doctor relationship (PDrQ-9, n=64).
Table S2 self-reported adherence to capecitabine (n=64)
MARS statements Number (%) of statements
Always Often Sometimes Rarely Never
i forget to take it 0 0 2 (3) 5 (8) 57 (89)
i alter the dose 0 0 2 (3) 2 (3) 60 (94)
i stop taking it for a while 1 (2) 0 0 2 (3) 61 (95)
i decide to miss out a dose 1 (2) 0 1 (2) 0 62 (97)
i take less than instructed 0 0 2 (3) 1 (2) 61 (95)
Notes: 13 participants were non-adherent according to Medication Adherence report scale (MArs). some participants stated multiple methods of deviation.
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Patient–doctor relationship and adherence to capecitabine in outpatients
Figure S2 Participant reported necessities of capecitabine therapy (Beliefs about Medicines Questionnaire – necessity scale, n=64).
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Figure S3 Participant reported concerns of capecitabine therapy (Beliefs about Medicines Questionnaire – concerns scale, n=64).
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